Introduction
============

Malignant tumors have been a major cause of death in economically developed countries and are expected to grow across the world because of the aging of the population [@B1]. It is estimated that 14.1 million new cancer cases and 8.2 million cancer deaths occurred in 2012 worldwide [@B1]. Despite significant advances in diagnosis and therapy, the prognosis of most malignant tumors is still unfavorable. The effective treatment of cancer relies heavily on better understanding the mechanism of the carcinogenesis, and discovering suitable tumor biomarkers to indicate the exact individualized therapy.

Macroautophagy (hereinafter referred to as autophagy) is a conserved programmed cell survival mechanism which refers to a basic catabolic process that delivers damaged intracellular organelles or proteins to the lysosomes for subsequent degradation and recycling of substrates in order to maintain cellular homeostasis [@B2]. The dysregulation of autophagy is involved in a broad spectrum of diseases, such as cancer, heart diseases and neurodegeneration diseases [@B3]-[@B5]. We can speculate that autophagy might play a paradoxical role in cancer according to its basic function. In early stage, autophagy may serve as a tumor suppressor by eliminating the defective organelles or toxic proteins, which may produce free radicals to cause genomic instability [@B6]. But in late stage, autophagy allows cancer cells to survive, invade, metastasize and evade cell death by eliminating deleterious cellular components and recycling nutrients in response to various stresses [@B7]. Exploiting autophagy for predictive biomarkers and anti-cancer therapeutic targets has become a field gaining ever increasing attention. However, until now, the exact role of autophagy in cancer is still unclear.

Mammalian sequestosome 1 (SQSTM1, hereinafter referred to as p62), is identified as an adaptor protein and functions in assembling protein complexes by several binding motifs [@B8]. Recently, p62 is considered as an indicator of functional basal autophagy [@B9]. P62 localizes at the autophagosomal membranes and works as an autophagy receptor through interacting with microtubule-associated protein 1 light chain 3 B (LC3B) and ubiquitinated cargoes [@B10]. During the process of autophagy flux, p62 itself is constantly degraded with the ubiquitinated substrates [@B11]. Thus, reduced p62 reflect active autophagy and conversely impaired autophagy can be indicated by an associated accumulation of p62 [@B12]. Exploring the role of p62 in cancer can promote a better understanding of the relationship between autophagy and cancer. However, there is still a lot of confusion about the clinical significance of p62 in most malignant tumors nowadays.

This study is conducted to investigate the differences of p62 expression level between tumor tissues and normal tissues, and the prognostic value of p62 in certain types of tumor. Ultimately, our results indicated that p62 protein elevated and mainly located in the cytoplasm in tumor cells in comparison with that in normal cells, and the cytoplasmic p62 accumulation predicated a poor prognosis in some types of malignant tumor.

Materials and methods
=====================

Search strategy
---------------

This meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) [@B13]. PubMed, PubMed Central (PMC), Embase, Ovid and Web of Science databases were used for literature search. The following keywords were employed: "sequestosome 1 or SQSTM1 or p62", "cancer or tumor or carcinoma" and "prognosis or outcome or survival". The latest search was carried out on July 1, 2018. We also consulted the references of identified articles for all relevant studies.

Selection criteria
------------------

Eligible study was enrolled in this meta-analysis in line with the following criteria: (1) p62 expression was detected in tumor tissues; (2) the outcomes of interest were in terms of overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), recurrence-free survival (RFS), metastasis-free survival (MFS) or disease-specific survival (DSS); and (3) sufficient data to estimate the hazard ratio (HR) and its 95% confidence intervals (CI) according to the p62 expression was reported. When the same patient cohort was reported in more than one study, the complete or the most recent one was selected. The exclusion criteria were following: (1) Articles without adequate survival data for extracting HRs and corresponding 95% CIs; (2) Articles in non-English; and (3) Reviews, summary of meeting, case reports, letters to the editor and non-human trials. Titles and abstracts of the identified articles were screened, and then comprehensive evaluation was carried out by viewing the full text carefully. Any disagreement was resolved via consensus.

Data extraction and quality assessment
--------------------------------------

Two reviewers independently extracted relevant information from all eligible studies. The following items were extracted: first author\'s name, publication year, country of origin, study recruitment years, period of follow-up, tumor type, staining pattern, age at the time of diagnosis, patients\' gender, tumor stage, sample size, detection method, cutoff value and assessments of outcomes. HR and the corresponding 95% CI of the high p62 expression group versus the low one for OS, PFS, DFS or DSS were also collected as applicable. If the survival outcomes were presented by both univariate and multivariate analyses, we chose the result of multivariate analysis. For studies in which HRs was not provided explicitly, we extracted the survival estimates from the original data or Kaplan-Meier curves using the Tierney\'s methods [@B14]. The level of p62 expression in tumor tissues and normal tissues was also extracted from the articles.

The quality of each study was assessed according to the Newcastle-Ottawa Scale (NOS) [@B15]. The NOS evaluates a study in three domains including selection of participants, comparability of study groups and the ascertainment of outcomes with the score ranged from 0 to 9. A study achieving a score of six or more was deemed as a high quality one.

P62 mRNA and protein expression profiles in various tumor tissues and normal tissues according to the Human Protein Atlas (HPA) and the Gene Expression Profiling Interactive Analysis (GEPIA)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The p62 mRNA and protein expression in different normal human tissues were generated in the HPA project (<https://www.proteinatlas.org>). RNA-seq results are reported as Fragments per Kilo-base of exon per Million reads (FPKM). The score of protein expression is based on the staining intensity and fraction of stained cells and describes the level of antibody staining observed in the annotated cell types as not detected, low, medium or high.

The p62 mRNA expression profile across all tumor samples and paired normal tissues were generated in GEPIA (<http://gepia.cancer-pku.cn/index.html>). The RNA-seq results are reported as number of transcripts per million (TPM).

P62 mRNA expression and patient survival in various tumors according to the Cancer Genome Atlas (TCGA) and the Human Protein Atlas (HPA)
----------------------------------------------------------------------------------------------------------------------------------------

The correlation between p62 expression at the mRNA level and patients survival in various tumors was examined based on the data from TCGA database (<https://cancergenome.nih.gov/>). The FPKMs (number Fragments per Kilo-base of exon per Million reads) were used for quantification of p62 mRNA level.

The prognosis of patients grouped by p62 mRNA expression was examined by Kaplan-Meier survival estimators, and the survival outcomes of the two groups were compared by log-rank tests. The median and maximally separated Kaplan-Meier curves are drew by the HPA. The log-rank P values less than 0.001 in maximally separated Kaplan-Meier analysis were considered significant statistically.

Statistical analysis
--------------------

The overexpression of p62 was defined according to the cutoff values provided by the original studies. Pooled HRs and 95% CIs were used to assess the relationship between p62 overexpression and prognosis of patients. Heterogeneity of HRs across the studies was evaluated using I-squared statistics [@B16]. I^2^ \> 50% indicated a statistically significant heterogeneity, which allowed the use of a random-effect model. Otherwise, a fixed-effect model was applied. To explore the possible sources of heterogeneity and further investigate the relationship between the p62 overexpression and survival of patients with different clinicopathological features, subgroup analyses were adopted. We also performed sensitivity analyses by omission of each single study to evaluate stability of the results. Potential publication bias was assessed by the Begg\'s funnel plot and Egger\'s test. STATA software version 12.0 (Stata Corporation, TX, USA) was utilized in this meta-analysis. In the process of meta-analysis, P \< 0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

According to the searching strategy described in the materials and methods, 9,655 articles were initially retrieved. Among them, 9,324 were excluded by screening the titles and abstracts, and then, 296 were excluded by the full-texts. At last, 30 articles met the inclusion criteria and were included into the meta-analysis after further evaluation. In addition, 5 studies reporting mean survival time of cancer patients were listed separately. The flow chart of the study search and selection process is reported in **Figure [1](#F1){ref-type="fig"}**.

The main features of the 30 included studies are summarized in **Table [1](#T1){ref-type="table"}**. A total of 14,072 patients from China, Germany, Japan, Korea, Norway, Switzerland, UK, and USA were diagnosed with various tumors, including breast cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric cancer, glioma, hepatocellular carcinoma, hypopharyngeal squamous cell carcinoma, lacrimal gland adenoid cystic carcinoma, melanoma, non-small cell lung cancer (NSCLC), oral squamous cell carcinoma, pancreatic cancer, prostate cancer, soft tissue sarcoma, thyroid cancer, and nasopharyngeal cancer. All of the studies were designed retrospectively and the year published ranged from 2007-2018. We selected OS, PFS and DSS as the main survival outcomes of all eligible studies for our meta-analysis. The quality of the 30 eligible studies enrolled in our meta-analysis was evaluated according to the NOS. The quality of the eligible studies ranged from 5 to 7, with a mean of 6.97. The main characteristics of another 5 studies reporting mean survival time were listed in **Table [3](#T3){ref-type="table"}**. Four studies represented the survival time as mean with 95% CI, and 1 study reported as mean ± standard deviation (SD). The cut-off values of p62 varied in different studies.

P62 mRNA and protein expression profiles in various tumor tissues and normal tissues
------------------------------------------------------------------------------------

The p62 mRNA and protein expression in different normal human tissues were generated according to the HPA. The p62 mRNA expressed in all normal tissues and the FPKM varied among different tissues (**Fig. [2](#F2){ref-type="fig"}**). Most normal tissues displayed moderate to strong cytoplasmic and nuclear p62 protein positivity, while cells in brain and cardiovascular system were weakly stained or negative (**Fig. [2](#F2){ref-type="fig"}**).

According to the data generated in GEPIA, the expression of p62 mRNA was significantly higher in diffuse large B-cell lymphoma (DLBC), liver hepatocellular carcinoma (LIHC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), and thymoma (THYM) than in their corresponding normal tissues (**Fig. [3](#F3){ref-type="fig"}A-B**). However, the p62 mRNA levels were lower in acute myeloid leukemia (LAML) in comparison with normal tissues (**Fig. [3](#F3){ref-type="fig"}A-B**).

The differences of p62 protein expression in tumor tissues and normal tissues were also tested based on the literature review (**Table [2](#T2){ref-type="table"}**). Among the 29 studies, twenty-five studies indicated that the expression of p62 protein was lower in normal tissues than in tumor tissues, which included breast cancer, colon adenocarcinoma, colorectal cancer, gastric cancer, melanoma, prostate cancer, oral squamous cell carcinomas, ovarian cancer, pancreatic cancer, head and neck carcinoma, glioblastoma and hepatocellular cancer (**Table [2](#T2){ref-type="table"}**). Two authors thought p62 protein level was lower in the colorectal cancer and gastric cancer compared with corresponding normal tissues [@B17], [@B18]. Another two authors thought there was no significant difference of p62 protein level between tumor tissues and normal tissues in prostate cancer and glioblastoma [@B19], [@B20].

Association between p62 expression and overall survival (OS)
------------------------------------------------------------

Twenty-two articles included 12,813 patients were collected to evaluate the relationship between p62 expression and OS. The random-effects model was employed because obvious heterogeneity was found in the meta-analysis (I^2^ = 79.9%, P \< 0.01). The pooled HR revealed that p62 over-expression was associated with a worse prognosis compared with the low expression group (HR 1.50, 95% CI: 1.17-1.93, P \< 0.05) (**Fig. [4](#F4){ref-type="fig"}A**).

Given the significant heterogeneity in the meta-analysis involving all 20 studies, we performed a series of subgroup analyses to estimate the possible correlation between p62 expression and OS based on three main features, including tumor stage, staining pattern, and tumor type. The first subgroup analysis was evaluated according to tumor stage. We observed that p62 over-expression in early stage tumor was related to worse OS (HR 1.85, 95% CI: 1.24-2.76, P \< 0.01) with no heterogeneity in the data (I^2^ = 0.0%, P = 0.668). As for late stage subgroup, there was only one study indicating no association between p62 expression and OS in colorectal cancer (**Fig. [4](#F4){ref-type="fig"}B**). Subgroup analysis based on staining pattern showed that high p62 expression in cytoplasm was associated with poor OS (HR 1.53, 95% CI: 1.03-2.27, P \< 0.05) whereas p62 over-expression in nucleus was not statistically associated with OS (HR 0.98, 95% CI: 0.49-1.97, P = 0.965) (**Fig. [4](#F4){ref-type="fig"}C**). In the subgroup analysis of OS by tumor type, we found that high p62 level was associated with poor OS of patients with nasopharyngeal cancer (HR 3.92, 95% CI: 1.74-8.82, P \< 0.01), non-small cell lung cancer (HR 2.93, 95% CI: 1.30-6.59, P \< 0.01), prostate cancer (HR 1.62, 95% CI: 1.33-1.97, P \< 0.01), glioma (HR 2.32, 95% CI: 1.03-5.20, P \< 0.05), oral squamous cell carcinoma (HR 1.76, 95% CI: 1.17-2.63, P \< 0.01), and epithelial ovarian cancer (HR 2.33, 95% CI: 1.43-3.79, P \< 0.01) (**Fig. [4](#F4){ref-type="fig"}D**). In esophageal cancer, high p62 level indicated a better OS (HR 0.55, 95% CI: 0.33-0.91, P \< 0.05) with only one study included. In other types of cancer such as colorectal cancer, gastric cancer, endometrial cancer, melanoma and breast cancer, p62 expression was not associated with the OS (**Fig. [4](#F4){ref-type="fig"}D**). The separate articles reporting mean survival time indicated that p62 expression had no effect on the OS in papillary thyroid carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and breast cancer (**Table [3](#T3){ref-type="table"}**).

Association between p62 expression and disease-free survival (DFS)
------------------------------------------------------------------

In our analysis, we merged DFS, RFS, MFS and PFS together considering the similarities among them. The effect of p62 expression on DFS was evaluated in 14 studies with 3,212 patients. A random-effect model was used to calculate the pooled HRs and 95% CIs due to the significant heterogeneity among studies (I^2^ = 67.6%, P\<0.01). The pooled results showed that p62 over-expression was associated with poor DFS in patients (HR 1.38, 95% CI: 1.06-1.79, P\<0.05) (**Fig. [5](#F5){ref-type="fig"}A**).

Given the significant heterogeneity in the meta-analysis involving all 14 studies, we performed a series of subgroup analyses to estimate the possible correlation between p62 expression and DFS based on tumor stage, staining pattern, and tumor type. In the subgroup analysis according to tumor stage, we found that in early stage group, p62 over-expression was related to worse DFS (HR 1.48, 95% CI: 1.11-1.95, P \< 0.01) with slight heterogeneity in the pooled data (I^2^ = 5.5%, P = 0.375) (**Fig. [5](#F5){ref-type="fig"}B**). As for late stage group, there was only one eligible study indicating that p62 over-expression was associated poor DFS in hypopharyngeal squamous cell carcinomas (**Fig. [5](#F5){ref-type="fig"}B**). In the subgroup analysis of DFS by staining pattern, we found that neither p62 overexpression in cytoplasm (HR 0.84, 95% CI: 0.42-1.67, P = 0.618) nor in nucleus (HR 0.73, 95% CI: 0.36-1.44, P = 0.360) was related to the DFS with significant heterogeneity appearing (**Fig. [5](#F5){ref-type="fig"}C**). In the subgroup analysis of DFS by tumor type, an increased p62 expression in tumor was associated with worse DFS of patients with nasopharyngeal cancer (HR 2.87, 95% CI: 1.16-7.12, P \< 0.05), hypopharyngeal cancer (HR 2.76, 95% CI: 1.05-7.25, P \< 0.05), non-small cell lung cancer (HR 1.66, 95% CI: 1.12-2.45, P \< 0.05) and glioma (HR 2.69, 95% CI: 1.14-6.31, P \< 0.05) (**Fig. [5](#F5){ref-type="fig"}D**). However, in other types of cancer such as breast cancer, hepatocellular carcinoma, melanoma and oral squamous cell carcinoma, there was no significant relationship between p62 expression and DFS statistically (**Fig. [5](#F5){ref-type="fig"}D**). In addition, four articles listed in the **Table [3](#T3){ref-type="table"}** reported that p62 expression was not associated with DFS in papillary thyroid carcinoma, lacrimal gland adenoid cystic carcinoma and breast cancer (**Table [3](#T3){ref-type="table"}**).

Association between p62 expression and disease-specific survival (DSS)
----------------------------------------------------------------------

DSS was reported in 8 articles covering 1,379 patients. A low heterogeneity (I^2^ = 30.6%, P = 0.16) was observed among these studies, so a fixed-effect model was utilized to analyze. The pooled HR for articles assessing the effect of p62 overexpression on DSS was 1.41 (95% CI: 1.16-1.73, P \< 0.01) (**Fig. [6](#F6){ref-type="fig"}A**).

Subgroup analyses by staining pattern and tumor type were also performed to further explore the possible correlation between p62 expression and DSS in patients with different clinicopathologic features. According to the staining pattern, we observed that high lever p62 in cytoplasm was related to worse DSS (HR 1.60, 95% CI: 1.15-2.24, P \< 0.01) with no heterogeneity in the pooled data (I^2^ = 0.0%, P = 0.621) (**Fig. [6](#F6){ref-type="fig"}B**). However, p62 high expression in nucleus was not related to DSS with significant heterogeneity appearing (I^2^ = 88.2%, P = 0.004) (**Fig. [6](#F6){ref-type="fig"} B**). In the subgroup analysis based on tumor type, pooled results indicated that high p62 level was associated with poor DSS of patients with oral squamous cell carcinoma (HR 2.09, 95% CI: 1.42-3.07, P \< 0.01) and non-small cell lung cancer (HR 2.00, 95% CI: 1.08-3.72, P \< 0.05) (**Fig. [6](#F6){ref-type="fig"}C**). In other types of cancer such as colorectal cancer, melanoma, soft tissue sarcoma and breast cancer, p62 expression was not associated with the DSS significantly (**Fig. [6](#F6){ref-type="fig"}C**).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analysis was performed to validate the influences of each study on the pooled results of OS, DFS and DSS by omitting each single study sequentially. The results indicated that the synthetic estimates of the effect of p62 overexpression on OS, DFS and DSS did not vary significantly with the omission of any individual study, which meant that the results of this meta-analysis were robust after using the leave-one-out method.

Begg\'s funnel plot and Egger\'s test were used to assess the publication bias of these applicable studies. The shapes of funnel plots for OS, DFS, and DSS showed no evidences of obvious asymmetry (**Fig. [7](#F7){ref-type="fig"}A-C**). The P-values of Begg\'s and Egger\'s tests were all over 0.05 (OS, P = 0.413 for the Begg\'s test, P = 0.368 for the Egger\'s test; DFS, P = 0.488 for the Begg\'s test, P = 0.143 for the Egger\'s test; DSS, P = 0.283 for the Begg\'s test, P = 0.728 for the Egger\'s test). The above results indicated that there was no significant publication bias existing in this meta-analysis.

P62 mRNA expression in tumors and patients\' survival
-----------------------------------------------------

Based on the data from TCGA and HPA, we assessed the association between p62 mRNA expression and OS in various tumors using Kaplan-Meier survival plots (**Fig. [8](#F8){ref-type="fig"}**). The association between p62 mRNA expression and OS in various malignant tumors was summarized in **Table [4](#T4){ref-type="table"}**. By generating the median and maximally separated Kaplan-Meier plots, we found that the high p62 mRNA expression group had significant worse OS only in the liver cancer analyzed with maximally separated Kaplan-Meier plots (**Fig. [8](#F8){ref-type="fig"}**). In other tumors, p62 mRNA level was not associated with the patients\' survival (**Table [4](#T4){ref-type="table"}**).

Discussion
==========

The expression of p62 mRNA and protein varied in different tissues, and in generally, the expression level of p62 protein was higher in malignant tumor tissues in comparison with normal tissues. This study analyzed the expression of p62 on the protein and mRNA levels in various types of tumors and evaluated its prognostic value. Furthermore, we performed subgroup analysis to explore the possible association between p62 expression and survival in tumor patients with different clinicopathologic features. A total of 14,072 tumor patients from 30 individual articles were enrolled in this study and the synthetic results indicated that p62 overexpression significantly predicted worse OS, DFS, and DSS in various tumors as a whole. Furthermore, subgroup analysis showed that the impact of p62 expression on tumor prognosis varied according to the differences in tumor stage, tumor type and p62 location. The adverse effect of p62 overexpression on OS, DFS and DSS was more certain in early stage than that in late stage. P62 accumulation in cytoplasm was associated with worse OS and DSS in various cancers whereas nuclear p62 was less effective. In the subgroup analysis by tumor type, we revealed that p62 overexpression was generally associated with worse survival in certain tumors such as non-small cell lung cancer, nasopharyngeal cancer, oral squamous cell carcinoma, glioma, prostate cancer, epithelial ovarian cancer, hypopharyngeal cancer, and melanoma. There were also 5 articles reporting that p62 expression had not impact on corresponding cancer prognosis separately [@B21]-[@B25]. Considering their small sample size and different presentation style, their results were not synthesized into the meta-analysis.

Recent studies reported that the p62 protein in benign tissues was mainly distributed in nuclei while p62 in tumor tissues was distributed obviously in cytoplasm [@B19], [@B26], [@B27]. Our pooled results showed that the cytoplasmic p62 accumulation predicted a worse prognosis in malignant tumors, and it was evident in the early stage tumors. However, nuclear p62 accumulation and p62 mRNA overexpression had no such effect statistically. Nuclear p62 protein and p62 mRNA might indicate the generation of p62, whereas the cytoplasm p62 depends on the dynamic balance between generation and degradation. The degradation of p62 along with other autophagosomal contents is a critical process during autophagy [@B2]. Therefore, accumulation of p62 reflects impaired autophagy, a process reported to be a key to the onset of tumorigenesis [@B7]. In contrast to the p62 generation, the degradation of p62 might have more important impact on the tumor survival. Consistent with the anti-tumor role of autophagy in early stage, it is reasonable that in early stage cytoplasmic p62 accumulation is associated with worse survival. Given the dual role of autophagy in tumorigenesis and progression, the autophagy related protein should be considered as a potential prognostic biomarker or therapeutic target according to the characteristics of tumor. Apart from the direct survival analysis, p62 expression was reported to be associated with lymph node status, distant metastasis, disease relapse and drug resistance [@B20], [@B28], [@B29]. High level of p62 also allowed cancer cells evade apoptosis and promote cancer progression through activating NF-κB and Nrf2 signaling pathways [@B30], [@B31]. P62 might participate in the regulation of tumor progression through multiple physiological processes in addition to autophagy pathway.

A recent study from Ruan et al. [@B32] which was published in Oncotarget, also examined the relationship between p62 expression and survival outcomes in solid tumor patients by combining 20 studies. However, there were another 15 published articles being suitable for this meta-analysis but not enrolled in their study. Our study updated the data to provide more accurate estimates with a stronger statistical power. Furthermore, we performed the subgroup analyses by tumor stage, p62 staining pattern and tumor type and found the strength of association between p62 and prognosis varied according to different clinicopathologic features. We also tested the predictive role of p62 mRNA level on patients\' survival in various types of tumors.

Despite our efforts to conduct a comprehensive analysis, several limitations remain to be recognized. First, the synthetic results are inevitably compromised by the potential publication bias because this meta-analysis is based on the reported studies. Predominantly positive results are more liable to be published and inflate our estimate for the association between p62 and patients\' survival. Second, all the included studies in our analysis are cohort studies and the cutoff values varied in different studies, which may influence the validity of p62 as a predictive biomarker in tumor prognosis. Third, certain HRs and 95% CIs were calculated from the Kaplan-Meier curves, so this might bring statistical deviations inevitably. Finally, there was significant heterogeneity in patient populations, clinical therapeutic methods and follow-up time. Although random-effects model and sensitivity analysis were carried out to address this heterogeneity, these statistical methods might not be sufficient.

Conclusions
===========

The pooled results of the meta-analysis suggest that p62 overexpression was associated with worse prognosis in certain types of tumors. Further subgroup analyses indicate that cytoplasmic p62 accumulation can be a prognostic marker for early stage tumors. Considering the limitations of this meta-analysis, this conclusion should be regarded with caution. Further well-designed studies with larger sample size are needed to verify the role of p62 expression on tumor prognosis.
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![The overview of p62 mRNA and protein expression in different normal human tissues. The data were generated in the Human Protein Atlas project (HPA). RNA-seq results generated in HPA are reported as Fragments per Kilo-base of exon per Million reads (FPKM). The score of protein expression describes the level of antibody staining observed in the annotated cell types as not detected (n), low (l), medium (m) or high (h). It is based on the staining intensity and fraction of stained cells. N/A not acquired.](jcav09p4072g002){#F2}

![The p62 mRNA expression profile across all tumor samples and paired normal tissues. The data were generated in the Gene Expression Profiling Interactive Analysis project (GEPIA). The RNA-seq results are reported as number of transcripts per million (TPM). (A) Dot plot. Each dot represents expression of sample. (B) Bar plot. The height of bar represents the median expression of certain tumor type or normal tissue. ACC, Adrenocortical carcinoma; BLCA, Bladder Urothelial Carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, Cholangio carcinoma; COAD, Colon adenocarcinoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA, Esophageal carcinoma; GBM, Glioblastoma multiforme; HNSC, Head and Neck squamous cell carcinoma; KICH, Kidney Chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LAML, Acute Myeloid Leukemia; LGG, Brain Lower Grade Glioma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; MESO, Mesothelioma; OV, Ovarian serous cystadenocarcinoma; PAAD, Pancreatic adenocarcinoma; PCPG, Pheochromocytoma and Paraganglioma; PRAD, Prostate adenocarcinoma; READ, Rectum adenocarcinoma; SARC, Sarcoma; SKCM, Skin Cutaneous Melanoma; STAD, Stomach adenocarcinoma; TGCT, Testicular Germ Cell Tumors; THCA, Thyroid carcinoma; THYM, Thymoma; UCEC, Uterine Corpus Endometrial Carcinoma; UCS, Uterine Carcinosarcoma; UVM, Uveal Melanoma.](jcav09p4072g003){#F3}

![Forest plots of studies evaluating the effect of p62 overexpression on overall survival (OS). (A) P62 overexpression was associated with worse OS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and OS according to (B) tumor stage, (C) staining pattern and (D) tumor type.](jcav09p4072g004){#F4}

![Forest plots of studies evaluating the effect of p62 overexpression on disease-free survival (DFS). (A) P62 overexpression was associated with worse DFS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and DFS according to (B) tumor stage, (C) staining pattern and (D) tumor type.](jcav09p4072g005){#F5}

![Forest plots of studies evaluating the effect of p62 overexpression on disease-specific survival (DSS). (A) P62 overexpression was associated with worse DSS in malignant tumors; Subgroup analyses investigating the relationship between p62 overexpression and DSS according to (B) staining pattern and (C) tumor type.](jcav09p4072g006){#F6}

![Begg\'s funnel plots for assessing potential publication bias. (A) Funnel plot analysis for overall survival (OS); (B) Funnel plot analysis for disease-free survival (DFS); (C) Funnel plot analysis for disease-specific survival (DSS).](jcav09p4072g007){#F7}

![Survival analysis of p62 mRNA expression according to the TCGA and HPA databases. (A) Liver cancer, (B) Lung cancer, (C) Breast cancer, (D) Cervical cancer, (E) Ovarian cancer, (F) Endometrial cancer. Purple lines represent high expression of p62 and blue lines represent low expression.](jcav09p4072g008){#F8}

###### 

Main characteristics of studies included in the meta-analysis

  Author               Year   Country       Study recruitment years   Follow-up time (months)             Tumor type             Staining pattern                 Age (years),mean                Gender (M/F)   Stage                          Sample size (n)   Detection method   Cutoff                                    Outcomes       NOS score
  -------------------- ------ ------------- ------------------------- ----------------------------------- ---------------------- -------------------------------- ------------------------------- -------------- ------------------------------ ----------------- ------------------ ----------------------------------------- -------------- -----------
  Yang Q [@B33]        2018   China         NA                        Median 50.86, range (12.93-72.23)   Nasopharyngeal         Whole cell                       73 (≤50); 43(\>50)              85/31          I-II 13; III-IV 103            116               IHC (Santa Cruz)   Score\>3                                  MFS; OS        6
  Terabe T [@B34]      2017   Japan         1997-2009                 NA                                  Oral                   Whole cell                       38 (≤65); 33(\>65)              40/31          I-II 37; III-IV 34             71                IHC (Abcam)        \>1%                                      RFS; DSS       6
  Xu LZ [@B35]         2017   China         1999-2008                 NA                                  Breast cancer          Whole cell                       Median 48                       Female 369     I 76, II 173, III 117, IV 2    369               IHC (NA)           NA                                        OS, DFS        8
  Arai A [@B36]        2017   Japan         1997-2008                 Max 120                             Hypopharyngeal         Whole cell                       Mean 65.1 range (45-81)         47/7           I 4; II 6; III 4; IV 40        54                IHC (MBL)          NA                                        DFS            5
  Nakayama S [@B37]    2017   Japan         2000-2006                 Mean 69.8 (range,2-131)             Colorectal             Cytoplasm                        NA                              71/47          I-II 63; III-IV 55             118               IHC (MBL)          \>10%                                     OS             7
  Niklaus M [@B38]     2017   Germany       1993-2005                 NA                                  Colon                  Cytoplasm                        Median 66 range (25-91)         160/132        NA                             292               IHC (LabForce)     Score≥1                                   OS             6
  Tang DY [@B39]       2016   UK            NA                        NA                                  Melanoma               Whole cell                       NA                              NA             II 75                          75                IHC (NA)           ≥20%                                      DFS            6
  Schlafli AM [@B40]   2016   Switzerland   1988-2008                 NA                                  NSCLC                  Whole cell; cytoplasm; nucleus   Median 67 range (39-83)         343/123        I-II                           466               IHC (MBL)          Score\>1                                  OS; RFS        7
  Cao QH [@B17]        2016   China         2002-2006                 NA                                  Gastric                Whole cell                       ≥58 174; \<58 178               235/117        I 41; II 83; III 192; IV 38    352               IHC (MBL)          Score\>8                                  OS             7
  Schmitz KJ [@B41]    2016   Germany       1996-1998                 Minimum 60                          Colorectal             Cytoplasm; nucleus               Mean 68.19 range (39-91)        66/61          I-II 65; III-IV 62             126               IHC (Santa Cruz)   NA                                        DSS            8
  Adams O [@B42]       2016   Switzerland   1991-2011                 NA                                  Esophageal             Whole cell; cytoplasm; nucleus   Median 69 range (32-89)         100/16         I 35; II 25; III 51; IV 5      116               IHC (MBL)          Score≥1                                   OS             7
  Masuda GO [@B43]     2016   Japan         NA                        Max 60                              Gastric                Whole cell                       Median 66 range (21-88)         290/220        I 250; II 76; III 108; IV 76   510               IHC (MBL)          \>20%                                     OS             8
  Jiang X [@B19]       2015   China         1999-2003                 120                                 Prostate               Whole cell                       Mean 69 range (52-85)           111/0          I-II 61; III 50                111               IHC (Enzo)         Score≥4                                   OS             7
  Iwadate R [@B44]     2015   Japan         1990-2007                 Median 98, range (61-235)           Endometrial            Cytoplasm                        NA                              0/194          I 143; II 12; III 32; IV 7     194               IHC (Santa Cruz)   ≥10%                                      OS             8
  Wang X [@B45]        2015   China         2006-2009                 Mean 48.5, range (3-96.5)           NSCLC                  Cytoplasm                        NA                              70/34          I-IV                           104               IHC (Abcam)        Score≥4                                   OS             7
  Burdelski C [@B46]   2015   Germany       1992-2012                 Median 36, range (1-241)            Prostate               Cytoplasm                        NA                              7822/0         pT2-pT4                        7822              IHC (Abcam)        NA                                        OS             8
  Zhao M [@B47]        2015   China         2009-2013                 6-60                                Glioma                 Cytoplasm                        47.8±16.4                       45/30          NA                             75                IHC (Santa Cruz)   Score≥3                                   PFS; OS        6
  Liu JL [@B26]        2014   China         2003-2008                 NA                                  Oral                   Cytoplasm; nucleus               55.57 ± 11.97                   187/8          I-IV                           195               IHC (Abcam)        Score≥100(cytoplasm);Score≥140(nucleus)   OS; DSS; RFS   8
  Ellis RA [@B48]      2014   UK            NA                        84                                  Melanoma               Whole cell                       NA                              NA             I-IV                           121               IHC (NA)           ≥20%                                      DFS; DSS; OS   7
  Iwadate R [@B49]     2014   Japan         1986-2006                 Average 59, range (1-120)           Ovarian                Cytoplasm                        107 ≤50 years, 159 \>50 years   0/266          I 150; II 281; III-IV 69       266               IHC (Santa Cruz)   ≥10%                                      OS             8
  Jin GZ [@B50]        2013   China         1996-2011                 Median 33, range (0.3-141)          Hepatocellular         Whole cell                       50.1 ± 10.9                     430/70         I 150; II 281; III-IV 69       500               IHC (Sigma)        \>25%                                     RFS; OS        8
  Inui T [@B51]        2013   Japan         NA                        NA                                  Oral                   Whole cell                       Median 64.8, range (27-92)      32/22          NA                             47                IHC (MBL)          \>20%                                     DSS            5
  Kim SK [@B52]        2013   Korea         2000-2008                 NA                                  Breast                 Whole cell                       40.2 ± 12.3                     0/204          NA                             204               IHC (Abcam)        Score≥2                                   DFS; OS        7
  Luo RZ [@B53]        2013   China         2000-2008                 Median 112, range (15-145)          Breast                 Whole cell                       Median 47, range (22-79)        0/163          I-II 121; III 42               163               IHC (Santa Cruz)   Score≥2                                   DFS; OS        7
  Park JM [@B54]       2013   USA           NA                        NA                                  Colorectal             Whole cell                       Median 63.5, range (26-81)      99/79          II 32; III 146                 178               IHC (MBL)          ≥50%                                      OS             7
  Chio J [@B55]        2013   Korea         2002-2003                 NA                                  Breast                 Cytoplasm; nucleus               48.6 ± 10.5                     0/489          NA                             489               IHC (Abcam)        Score≥2(cytoplam);\>10%(nucleus)          DFS; OS        8
  Sorbye SW [@B56]     2012   Norway        1973-2006                 NA                                  Soft tissue sarcomas   Whole cell                       Mean 55, range (0-89)           81/112         NA                             187               IHC (BD)           Score≥0.33                                DSS            7
  Inoue D [@B57]       2012   Japan         1993-1995                 Mean 54.2, range (0.5-112)          NSCLC                  Cytoplasm                        Mean 65.6, range (23-82)        78/31          I 69; II-III 40                109               IHC (Progen)       \>10%                                     DSS            6
  Kim S [@B58]         2012   Korea         2000-2005                 59.2±27.9                           Breast cancer          Cytoplasm; nucleus               47.3±12.1                       Female 119     NA                             119               IHC (Abcam)        Score≥2                                   OS, DFS        6
  Rolland P [@B59]     2007   UK            1987-1998                 Median 76                           Breast                 Cytoplasm                        ≤70                             0/523          NA                             523               IHC (INC)          \>5%                                      DSS            8

NA, not acquired; M, male; F, female; NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; OS, overall survival; MFS, metastasis free survival; DFS, disease free survival; DSS, disease-specific survival; RFS, relapse free survival; PFS, progression free survival

###### 

Literature review on p62 expression in various normal tissues and tumor tissues.

  Author                    Year   Tumor type       Detection method                 P62 protein abundance              P value                                 
  ------------------------- ------ ---------------- -------------------------------- ---------------------------------- --------------------------------------- -----------------
  Xu LZ [@B35]              2017   Breast           WB (NA)                          Low (10)                           High (10)                               \<0.01
  Li SS [@B60]              2017   Breast           WB (Santa Cruz; CST)             Low (5)                            High (5)                                \<0.01
  Kim SK [@B52]             2013   Breast           IHC (Abcam)                      Low (156)                          High (16)                               \<0.05
  Tang J [@B61]             2012   Breast           WB (Santa Cruz)                  Low (4)                            High (4)                                NA
  Thompson HG [@B62]        2003   Breast           WB (Transduction Laboratories)   Low (9)                            High (4)                                \<0.05
  Nakayama S [@B37]         2017   Colorectal       IHC (MBL)                        Low (28)                           High (118)                              0.018
  Niklaus M [@B38]          2017   Colon            IHC (LabForce)                   Low                                High                                    \<0.001
  Schmitz KJ [@B41]         2016   Colorectal       IHC (Santa Cruz)                 Low (127)                          High (127)                              NA
  Mohamed A [@B23]          2015   Colon            IHC (Abcam)                      Low (4)                            High (45)                               NA
  Park JM [@B54]            2013   Colorectal       IHC (MBL)                        Low (171)                          High (171)                              NA
  Chang LC [@B18]           2013   Colorectal       IHC (Abcam)                      High (83)                          Low (83)                                \<0.05
  Cao QH [@B17]             2016   Gastric          WB (MBL); IHC (MBL)              High                               Low                                     NA
  Masuda GO [@B43]          2016   Gastric          IHC (MBL)                        Low                                High                                    NA
  Mohamed A [@B23]          2015   Gastric          IHC (Abcam)                      Low (6)                            High (61)                               NA
  Tang DY [@B39]            2016   Melanoma         IHC (NA)                         Low                                High                                    \<0.01
  Ellis RA [@B48]           2014   Melanoma         IHC (NA)                         0.51% (29)                         14.82% (121)                            \<0.0001
  Falasca L [@B63]          2015   Prostate         IHC (MBL)                        Low (12)                           High (26)                               \<0.05
  Jiang X [@B19]            2015   Prostate         IHC (MBL)                        Mainly in the nuclei               Mainly in the cytoplasm                 No significance
  Burdelski C [@B46]        2015   Prostate         IHC (Abcam)                      Low                                High                                    NA
  Giatromanolaki A [@B64]   2014   Prostate         IHC (Abcam)                      Low (NA)                           High (96)                               NA
  Kitamura H [@B27]         2006   Prostate         IHC (Santa Cruz)                 Low and mainly in the nuclei (9)   High and mainly in the cytoplasm (45)   NA
  Liu JL [@B26]             2014   Oral             IHC (Abcam)                      Mainly in the nuclei               Mainly in the cytoplasm                 \<0.001
  Inui T [@B51]             2013   Oral             IHC (MBL)                        Low (14)                           High (54)                               \<0.0001
  Ju LL [@B28]              2016   Ovarian          IHC (NA)                         Low (13)                           High (47)                               \<0.05
  Mohamed A [@B23]          2015   Pancreatic       IHC (Abcam)                      Low (4)                            High (18)                               NA
  Kuo WL [@B65]             2014   Head and neck    IHC (MBL)                        Low (76)                           High (199)                              \<0.01
  Okada M [@B20]            2014   Ameloblastoma    IHC (MBL)                        Positive rate 67% (9)              Positive rate 69% (49)                  No significance
  Giatromanolaki A [@B66]   2014   Glioblastoma     IHC (Abcam); WB (Abcam)          Low                                High                                    NA
  Jin GZ [@B50]             2013   Hepatocellular   IHC (Sigma)                      Low (46)                           High (51)                               \<0.0001

NA, not acquired; N, normal tissues; T, tumor tissues; n, number; IHC, immunohistochemistry; WB, western blot

###### 

Main characteristics of 5 studies investigating the relationship between p62 expression and tumor prognosis but not combined into the meta-analysis

  Author             Year   Country   Recruitment years   Tumor type                                Staining pattern   Age(years)                   Gender   Sample size(n)   Detection method   Cutoff    Outcomes   Survival mean (95% CI)/mean±SD months   P value         
  ------------------ ------ --------- ------------------- ----------------------------------------- ------------------ ---------------------------- -------- ---------------- ------------------ --------- ---------- --------------------------------------- --------------- -------
  Kim HM [@B21]      2017   Korea     2012-2013           Papillary thyroid carcinoma               Whole cell         NA                           NA       342              IHC (Abcam)        \>10%     DFS        105 (101-109)                           107 (104-110)   0.643
  Kim HM [@B21]      2017   Korea     2012-2013           Papillary thyroid carcinoma               Whole cell         NA                           NA       342              IHC (Abcam)        \>10%     OS         108 (106-111)                           106 (103-109)   0.14
  Koo JS [@B22]      2016   Korea     1997-2012           Lacrimal gland adenoid cystic carcinoma   Whole cell         21-72                        8/3      11               IHC (Abcam)        Score≥2   DFS        45 (31-58)                              18 (0-52)       0.1
  Mohamed A [@B23]   2015   USA       2000-2013           Gastric cancer                            Nucleus            Median 64, range (53-84)     42/19    61               IHC (Abcam)        \>20%     OS         2.60 ± 1.33                             2.37 ± 0.19     0.48
  Mohamed A [@B23]   2015   USA       2000-2013           Gastric cancer                            Cytoplasm          Median 64, range (53-84)     42/19    61               IHC (Abcam)        \>20%     OS         2.46 ± 1.36                             2.47 ± 1.10     0.97
  Mohamed A [@B23]   2015   USA       2000-2013           Colorectal cancer                         Nucleus            Median 60.6, range (50-81)   28/17    45               IHC (Abcam)        \>20%     OS         2.76 ± 1.71                             2.45 ± 1.66     0.57
  Mohamed A [@B23]   2015   USA       2000-2013           Colorectal cancer                         Cytoplasm          Median 60.6, range (50-81)   28/17    45               IHC (Abcam)        \>20%     OS         2.63 ± 2.05                             2.66 ± 1.59     0.97
  Mohamed A [@B23]   2015   USA       2000-2013           Pancreatic cancer                         Nucleus            Median 64, range (50-75)     10/5     18               IHC (Abcam)        \>20%     OS         1.34 ± 1.02                             1.72 ± 1.04     0.55
  Mohamed A [@B23]   2015   USA       2000-2013           Pancreatic cancer                         Cytoplasm          Median 64, range (50-75)     10/5     18               IHC (Abcam)        \>20%     OS         1.77 ± 1.02                             1.47 ± 1.06     0.56
  Cha YJ [@B24]      2014   Korea     2000-2012           Breast cancer                             Whole cell         63 (\<50); 51(≥50)           0/114    114              IHC (Abcam)        Score≥2   DFS        163 (156-169)                           93 (89-89)      0.853
  Cha YJ [@B24]      2014   Korea     2000-2012           Breast cancer                             Whole cell         63 (\<50); 51(≥50)           0/114    114              IHC (Abcam)        Score≥2   OS         162 (155-169)                           93 (89-97)      0.954
  Kim JY [@B25]      2014   Korea     2005-2012           Breast cancer                             Cytoplasm          34 (≤35); 300(\>35)          0/334    334              IHC (Abcam)        Score≥2   DFS        112 (99-125)                            117 (111-124)   0.907
  Kim JY [@B25]      2014   Korea     2005-2012           Breast cancer                             Cytoplasm          34 (≤35); 300(\>35)          0/334    334              IHC (Abcam)        Score≥2   OS         117 (106-128)                           126 (120-131)   0.289

NA, not acquired; M, male; F, female; n, number; IHC, immunohistochemistry; CI, confidence interval; SD, standard deviation; DFS, disease free survival; OS, overall survival.

###### 

Association between p62 mRNA level and OS based on the TCGA and HPA databases

  Tumor type             Best separation              Median separation          
  ---------------------- ----------------- ---------- ------------------- ------ ----------
  Liver cancer           110.7             2.31E-05                       66.4   4.09E-02
  Lung cancer            38.7              1.34E-01                       38.6   1.44E-01
  Breast cancer          46.5              1.08E-01                       33.9   7.71E-01
  Cervical cancer        36.4              1.39E-01                       28.4   9.65E-01
  Ovarian cancer         22.8              5.65E-02                       34.6   8.04E-01
  Endometrial cancer     24.6              9.45E-02                       26.8   4.69E-01
  Glioma                 26.2              1.21E-02                       28.0   4.42E-02
  Thyroid cancer         70.3              4.41E-02                       60.4   5.27E-01
  Urothelial cancer      22.0              2.01E-01                       28.7   9.85E-01
  Renal cancer           58.1              9.52E-02                       40.1   8.98E-01
  Prostate cancer        24.6              1.70E-01                       29.4   4.24E-01
  Testis cancer          16.6              8.68E-03                       12.3   2.02E-02
  Stomach cancer         24.3              3.21E-01                       32.8   5.59E-01
  Colorectal cancer      49.2              3.19E-01                       38.7   4.88E-01
  Pancreatic cancer      41.6              1.66E-01                       38.8   3.80E-01
  Head and neck cancer   38.1              1.08E-01                       26.7   2.00E-01
  Melanoma               40.6              2.34E-01                       51.5   6.22E-01

FPKM, Fragments per Kilo-base of exon per Million reads
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